Cargando…
The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in di...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928415/ https://www.ncbi.nlm.nih.gov/pubmed/33680930 http://dx.doi.org/10.3389/fonc.2020.608257 |
_version_ | 1783659852490342400 |
---|---|
author | Xiong, Dandan He, Rongquan Dang, Yiwu Wu, Huayu Feng, Zhenbo Chen, Gang |
author_facet | Xiong, Dandan He, Rongquan Dang, Yiwu Wu, Huayu Feng, Zhenbo Chen, Gang |
author_sort | Xiong, Dandan |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in dissatisfactory treatment result. Therefore, it is urgent to determine effective and sensitive diagnostic and prognostic indicators and to determine new therapeutic targets. Circular RNA (circRNA) is a type of non-coding RNA that has been neglected for a long time. In recent years, it has been proved to play an important role in the development of many human diseases. Increasing evidence shows that change in circRNA expression has an extensive effect on the biological behavior of HCC. In this study, we comprehensively tracked the latest progress of circRNA in the pathogenesis of HCC, and reviewed its role as a biomarker for diagnosis and prognosis prediction in patients with HCC. In addition, we also summarized the potential of circRNA as therapeutic target in HCC and its relationship with HCC drug resistance, providing clues for the clinical development of circRNA-based therapeutic strategies. |
format | Online Article Text |
id | pubmed-7928415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79284152021-03-04 The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma Xiong, Dandan He, Rongquan Dang, Yiwu Wu, Huayu Feng, Zhenbo Chen, Gang Front Oncol Oncology Hepatocellular carcinoma (HCC) is one of the main causes of tumor-related deaths worldwide. Due to the lack of obvious early symptoms and the lack of sensitive screening indicators in the early stage of HCC, the vast majority of patients are diagnosed with advanced or metastatic HCC, resulting in dissatisfactory treatment result. Therefore, it is urgent to determine effective and sensitive diagnostic and prognostic indicators and to determine new therapeutic targets. Circular RNA (circRNA) is a type of non-coding RNA that has been neglected for a long time. In recent years, it has been proved to play an important role in the development of many human diseases. Increasing evidence shows that change in circRNA expression has an extensive effect on the biological behavior of HCC. In this study, we comprehensively tracked the latest progress of circRNA in the pathogenesis of HCC, and reviewed its role as a biomarker for diagnosis and prognosis prediction in patients with HCC. In addition, we also summarized the potential of circRNA as therapeutic target in HCC and its relationship with HCC drug resistance, providing clues for the clinical development of circRNA-based therapeutic strategies. Frontiers Media S.A. 2021-02-17 /pmc/articles/PMC7928415/ /pubmed/33680930 http://dx.doi.org/10.3389/fonc.2020.608257 Text en Copyright © 2021 Xiong, He, Dang, Wu, Feng and Chen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xiong, Dandan He, Rongquan Dang, Yiwu Wu, Huayu Feng, Zhenbo Chen, Gang The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title | The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title_full | The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title_fullStr | The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title_full_unstemmed | The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title_short | The Latest Overview of circRNA in the Progression, Diagnosis, Prognosis, Treatment, and Drug Resistance of Hepatocellular Carcinoma |
title_sort | latest overview of circrna in the progression, diagnosis, prognosis, treatment, and drug resistance of hepatocellular carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928415/ https://www.ncbi.nlm.nih.gov/pubmed/33680930 http://dx.doi.org/10.3389/fonc.2020.608257 |
work_keys_str_mv | AT xiongdandan thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT herongquan thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT dangyiwu thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT wuhuayu thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT fengzhenbo thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT chengang thelatestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT xiongdandan latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT herongquan latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT dangyiwu latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT wuhuayu latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT fengzhenbo latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma AT chengang latestoverviewofcircrnaintheprogressiondiagnosisprognosistreatmentanddrugresistanceofhepatocellularcarcinoma |